Diagnostic utility of P63 and CD10 in distinguishing cutaneous spindle cell/sarcomatoid squamous cell carcinomas and atypical fibroxanthomas.
The pathologic distinction of atypical fibroxanthomas (AFXs) from cutaneous spindle cell/sarcomatoid squamous cell carcinomas (SCSCCs) may occasionally pose a significant diagnostic challenge, given the substantial clinicopathologic overlap between these lesions. Recent studies indicate that p63 and CD10 are expressed in significant proportions of SCSCC and AFX, respectively. The purpose of this study is to investigate the utility of CD10 and p63 in distinguishing cutaneous SCSCCs and AFXs. The immunohistochemical expression of p63, CD10, cytokeratin AE-1/3, cytokeratin 5/6 and a cytokeratin cocktail (Kermix) was evaluated in an archived group of 23 AFXs and 10 SCSCCs. CD10 was positive in 18/23 AFXs (78%), with most demonstrating strong and/or diffuse staining. Three of 23 AFXs (13%), all negative for cytokeratins, showed focal and weak nuclear staining for p63. Two of 23 AFXs (9%) demonstrated very focal or weak staining for only one cytokeratin; in both cases, p63 and CD10 were negative. One AFX was negative with all immunostains. CD10 was positive in 6/10 SCSCCs (60%), with half demonstrating strong and/or diffuse staining. P63 was positive in 9/10 SCSCCs (90%), with most demonstrating strong and diffuse staining. One SCSCC was negative for p63, but positive with two cytokeratin immunostains. In conclusion, the expression of any of the cytokeratins evaluated herein significantly distinguished AFX from SCSCC. CD10 used in isolation, however, was not useful in making this distinction (positive in 18/23 AFXs versus 6/10 SCSCCs, p=0.4). The addition of CD10 to a panel that includes p63 did not provide any additional information to that obtained from the latter alone. Overall, the most effective combination to distinguish AFX from SCSCC was p63 and cytokeratin AE-1/3. Positivity for both p63 and cytokeratin AE-1/3 was seen in 9/10 SCSCCs (90%) and was not observed in any of the 23 AFXs (p<0.0001). The usefulness of CD10 in this differential diagnosis is limited.
Hall
Jordan M
JM
Department of Pathology and Laboratory Services, Brooke Army Medical Center, Fort Sam Houston, TX 78235, USA. Jordan.hall@lackland.af.mil
Saenger
Jeff S
JS
Fadare
Oluwole
O
J Clin Pathol. 2007 Jun;60(6):716-7
17483246
Australas J Dermatol. 2005 Nov;46(4):235-8
16197421
Am J Dermatopathol. 2005 Apr;27(2):181
15798451
Semin Diagn Pathol. 1993 May;10(2):148-58
8396271
Semin Cutan Med Surg. 1999 Mar;18(1):78-83
10188846
J Cutan Pathol. 2006 Jun;33(6):413-7
16776716
Dermatol Surg. 2004 Dec;30(12 Pt 2):1561-4
15606841
J Cutan Pathol. 2002 Oct;29(9):517-23
12358808
Cancer. 1973 Jun;31(6):1541-52
4709969
Histopathology. 1993 Mar;22(3):247-54
7684354
Mod Pathol. 2005 Nov;18(11):1471-81
15976812
Dermatol Surg. 1996 Mar;22(3):243-54
8599736
Tex State J Med. 1963 Jul;59:652-89
13953663
Virchows Arch. 2002 Jan;440(1):36-44
11942575
J Cutan Pathol. 1992 Aug;19(4):286-93
1385501
J Cutan Pathol. 2006 Mar;33(3):191-206
16466506
J Cutan Pathol. 2001 Nov;28(10):520-4
11737521
J Cutan Pathol. 2007 May;34(5):415-9
17448198
Dermatol Surg. 2005 Feb;31(2):221-5; discussion 225
15762219
Cancer. 1986 Jan 15;57(2):368-76
3942970
J Cutan Pathol. 2003 Jul;30(6):393-400
12834489
Am J Surg Pathol. 1993 Dec;17(12):1199-209
8238729